HomeCompanyTechnologyPipelineInvestors & MediaContact

Our TCR-T cells are engineered to target virus-derived peptides presented on MHC class I on cell surface.

I. Virus-infected cells

Upon virus infection, viral proteins are expressed in the infected cells. These viral proteins are degraded into viral peptides and assembled with MHC class I to be presented onto the cell surface. These peptide-MHC I complexes on the infected cell surface are recognized by cytotoxic T cells, leading to the release of cytokines and triggering antiviral responses.

II. Virus-related cancer cells

Upon virus infection, viral proteins are expressed in the infected cells. These viral proteins are degraded into viral peptides and assembled with MHC class I to be presented onto the cell surface. These peptide-MHC I complexes on the infected cell surface are recognized by cytotoxic T cells, leading to the release of cytokines and triggering antiviral responses.

Clinical Application

1. The patient undergoes leukapheresis to isolate white blood cells.

2. T cells from the patient are expanded and activated in Lion TCR’s GMP cell production center.

3. Genetic material encoding our virus- or cancer-targeting TCR are introduced into the activated T cells by viral transduction or electroporation.

4. The patient’s T cells now express the relevant TCR that target virus-infected or virus-related cancer cells.

5. Following phenotypic and functional validation, the TCR engineered T cells are infused back to the patient.

Publications

Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3

Koh S et al. Gastroenterology (2018)

T-cell therapy for chronic viral hepatitis

Bertoletti A et al. Cytotherapy (2017)

Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection

Kah J et al. Journal of Clinical Investigation (2017)

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient

Qasim W et al. Journal of Hepatology (2015)

T cell receptor-therapy in HBV-related hepatocellularcarcinoma

Bertoletti A et al. Oncoimmunology (2015)

Immunoprevalence and immunodominance of HLA-Cw∗ 0801-restricted T cell response targeting the hepatitis B virus envelope transmembrane region

Tan AT et al. Journal of Virology (2014)

TCRs in Development

Our library of TCRs recognizes viral peptides expressed on MHC Class I restricted for the Asian population.

We are actively extending our proprietary TCR therapy platform to target more viruses, particularly those prevalent in Asia, for example, HBV, EBV and CMV.

pipeline